Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
Rhea-AI Summary
Cabaletta Bio (Nasdaq: CABA) announced participation in five investor conferences in November–December 2025 with scheduled webcasted fireside chats and investor meetings.
Key dates and times: Guggenheim fireside chat on Nov 11, 2025 at 10:30 a.m. ET; TD Cowen on Nov 13, 2025 at 11:00 a.m. ET; Jefferies (London) on Nov 17, 2025 at 1:30 p.m. GMT (meetings Nov 17–18); Evercore on Dec 2, 2025 at 8:20 a.m. ET; and Citi on Dec 3, 2025 at 1:45 p.m. ET.
All webcasted fireside chats will be available on the company's News and Events website page and replays will be posted for 30 days. The company will be available for in-person and virtual investor meetings as noted per event.
Positive
- None.
Negative
- None.
News Market Reaction 12 Alerts
On the day this news was published, CABA declined 10.30%, reflecting a significant negative market reaction. Argus tracked a trough of -10.0% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $29M from the company's valuation, bringing the market cap to $252M at that time.
Data tracked by StockTitan Argus on the day of publication.
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in November and December:
- Guggenheim’s 2nd Annual Healthcare Innovation Conference: Webcasted fireside chat at 10:30 a.m. ET on Tuesday, November 11, 2025, in Boston, MA. The Company will also be available for meetings with investors.
- TD Cowen Immunology & Inflammation Summit: Fireside chat at 11:00 a.m. ET on Thursday, November 13, 2025. The Company will also be available for virtual meetings with investors.
- Jefferies Global Healthcare Conference in London: Webcasted fireside chat at 1:30 p.m. GMT on Monday, November 17, 2025, in London, UK. The Company will also be available for meetings with investors from November 17-18, 2025.
- 8th Annual Evercore Healthcare Conference: Webcasted fireside chat at 8:20 a.m. ET on Tuesday, December 2, 2025, in Coral Gables, FL. The Company will also be available for meetings with investors.
- Citi’s 2025 Global Healthcare Conference: Webcasted fireside chat at 1:45 p.m. ET on Wednesday, December 3, 2025, in Miami, FL. The Company will also be available for meetings with investors.
The webcasted fireside chats will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com